Research details developments in the demand for Corneal Neovascularization – Pipeline Review, H1 2016


“The Report Corneal Neovascularization – Pipeline Review, H1 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Global Markets Directs, Corneal Neovascularization – Pipeline Review, H1 2016, provides an overview of the Corneal Neovascularization pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Corneal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at:


– The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization

– The report reviews pipeline therapeutics for Corneal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Corneal Neovascularization therapeutics and enlists all their major and minor projects

– The report assesses Corneal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Corneal Neovascularization

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Corneal Neovascularization

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Corneal Neovascularization pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read our latest Press Release at

Table Of Content

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Corneal Neovascularization Overview 6

Therapeutics Development 7

Pipeline Products for Corneal Neovascularization – Overview 7

Pipeline Products for Corneal Neovascularization – Comparative Analysis 8

Corneal Neovascularization – Therapeutics under Development by Companies 9

Corneal Neovascularization – Therapeutics under Investigation by Universities/Institutes 10

Corneal Neovascularization – Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Corneal Neovascularization – Products under Development by Companies 13

Corneal Neovascularization – Products under Investigation by Universities/Institutes 14

Corneal Neovascularization – Companies Involved in Therapeutics Development 15

Amakem NV 15

Gene Signal International SA 16

Sirnaomics, Inc. 17

Corneal Neovascularization – Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

aganirsen – Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AMA-0526 – Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization – Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Gene Therapy to Inhibit Vascular Endothelial Growth Factor A for Corneal

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074